Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUAISHOU-W
01024
5
JD HEALTH
06618
| (Q1)Nov 30, 2025 | (FY)Aug 31, 2025 | (Q9)May 31, 2025 | (Q6)Feb 28, 2025 | (Q1)Nov 30, 2024 | (FY)Aug 31, 2024 | (Q9)May 31, 2024 | (Q6)Feb 29, 2024 | (Q1)Nov 30, 2023 | (FY)Aug 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 14.81%1.03T | 9.56%3.4T | 10.57%2.62T | 11.96%1.79T | 10.40%895.19B | 12.19%3.1T | 10.40%2.37T | 8.97%1.6T | 13.18%810.83B | 20.23%2.77T |
| Operating income | 14.81%1.03T | 9.56%3.4T | 10.57%2.62T | 11.96%1.79T | 10.40%895.19B | 12.19%3.1T | 10.40%2.37T | 8.97%1.6T | 13.18%810.83B | 20.23%2.77T |
| Cost of sales | -12.86%-460.04B | -9.85%-1.57T | -11.09%-1.21T | -10.83%-835.37B | -10.76%-407.62B | -7.56%-1.43T | -4.78%-1.09T | -3.85%-753.76B | -9.49%-368.01B | -21.56%-1.33T |
| Operating expenses | -12.86%-460.04B | -9.85%-1.57T | -11.09%-1.21T | -10.83%-835.37B | -10.76%-407.62B | -7.56%-1.43T | -4.78%-1.09T | -3.85%-753.76B | -9.49%-368.01B | -21.56%-1.33T |
| Special items of gross profit | 0.00%-1M | ---- | ---- | ---- | ---1M | 0.00%-1M | 0.00%-1M | ---- | ---- | ---1M |
| Gross profit | 16.43%567.7B | 9.31%1.83T | 10.13%1.41T | 12.96%954.83B | 10.11%487.57B | 16.48%1.67T | 15.68%1.28T | 13.99%845.24B | 16.45%442.82B | 19.02%1.44T |
| Selling expenses | -9.52%-362.06B | -7.58%-1.28T | -8.93%-964.99B | -9.95%-653.16B | -9.68%-330.58B | -12.65%-1.19T | -13.55%-885.87B | -13.33%-594.07B | -13.72%-301.4B | -17.13%-1.05T |
| Special items of operating profit | 833.87%5.27B | -15.68%13.11B | -14.89%7.41B | -56.96%2.55B | -89.29%564M | 1,823.39%15.55B | 68.61%8.7B | 100.24%5.91B | 187.96%5.26B | 90.38%-902M |
| Adjustment items of operating profit | ---- | ---- | ---- | ---- | 200.00%1M | --1M | 0.00%-1M | --1M | 0.00%-1M | ---- |
| Operating profit | 33.87%210.91B | 12.65%564.27B | 12.23%450.95B | 18.33%304.22B | 7.41%157.56B | 31.44%500.9B | 21.55%401.8B | 16.72%257.09B | 25.29%146.69B | 28.17%381.09B |
| Financing income | -54.22%19.39B | 47.10%99.14B | -5.72%79.02B | 39.26%65.83B | 131.89%42.35B | 1.02%67.4B | 132.30%83.82B | 176.86%47.27B | 48.20%18.26B | -46.12%66.72B |
| Financing cost | -10.52%-3.63B | -15.61%-12.83B | -20.55%-9.47B | -27.45%-6.32B | -32.79%-3.29B | -12.27%-11.1B | -5.37%-7.85B | 27.45%-4.96B | 4.33%-2.48B | -30.79%-9.89B |
| Adjustment items of earning before tax | ---- | ---- | --1M | 0.00%-1M | ---- | ---1M | ---- | ---1M | ---- | ---- |
| Earning before tax | 15.29%226.67B | 16.76%650.57B | 8.95%520.51B | 21.49%363.72B | 21.01%196.61B | 27.24%557.2B | 33.01%477.77B | 29.89%299.4B | 28.12%162.47B | 5.88%437.92B |
| Tax | -21.03%-68.15B | -17.01%-191.42B | -10.33%-160.9B | -27.22%-114.44B | -17.90%-56.31B | -33.28%-163.6B | -39.82%-145.83B | -36.57%-89.96B | -29.16%-47.76B | 4.73%-122.75B |
| After-tax profit from continuing operations | 12.98%158.51B | 16.65%459.15B | 8.34%359.61B | 19.02%249.28B | 22.31%140.3B | 24.89%393.61B | 30.22%331.94B | 27.22%209.44B | 27.69%114.71B | 10.68%315.17B |
| Adjustment items of earning after tax | 0.00%-1M | ---- | ---1M | ---- | 0.00%-1M | ---- | ---- | ---- | 0.00%-1M | ---1M |
| Earning after tax | 12.98%158.51B | 16.65%459.15B | 8.34%359.61B | 19.02%249.28B | 22.31%140.3B | 24.89%393.61B | 30.22%331.94B | 27.22%209.44B | 27.69%114.71B | 10.68%315.17B |
| Minority profit | 32.75%11.07B | 21.00%26.14B | 7.38%20.51B | 16.18%15.72B | 20.74%8.34B | 14.06%21.61B | 16.55%19.1B | 20.36%13.53B | 45.19%6.91B | 65.93%18.94B |
| Special items of profit attributable to shareholders | --2M | 0.00%2M | ---- | --2M | ---- | 0.00%2M | --2M | ---- | --2M | --2M |
| Adjustment items of profit attributable to shareholders | ---1M | 0.00%-1M | ---- | ---1M | ---- | 0.00%-1M | ---1M | ---- | ---1M | ---1M |
| Profit attributable to shareholders | 11.73%147.45B | 16.40%433.01B | 8.39%339.1B | 19.22%233.57B | 22.41%131.96B | 25.58%372B | 31.16%312.84B | 27.72%195.91B | 26.71%107.8B | 8.38%296.23B |
| Basic earnings per share | 11.71%480.55 | 16.37%1.41K | 8.37%1.11K | 19.19%761.38 | 22.39%430.19 | 25.55%1.21K | 31.12%1.02K | 27.68%638.79 | 26.67%351.5 | 8.33%966.09 |
| Diluted earnings per share | 11.73%479.89 | 16.39%1.41K | 8.39%1.1K | 19.21%760.21 | 22.41%429.51 | 25.54%1.21K | 31.11%1.02K | 27.65%637.68 | 26.62%350.88 | 8.32%964.48 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion |
| Auditor | -- | Deloitte Touche Tohmatsu LLC (Deloitte Limited) | -- | -- | -- | Deloitte Touche Tohmatsu LLC (Deloitte Limited) | -- | -- | -- | Deloitte Touche Tohmatsu LLC (Deloitte Limited) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.